share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  05/16 12:36
Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has filed an amendment to its Form 8-K with the U.S. Securities and Exchange Commission. The amendment, dated May 15, 2024, clarifies details regarding the company's previously announced reverse stock split. The amendment specifies that only the company's common stock, not its public warrants, will begin trading on a split-adjusted basis at the market open on May 17, 2024. Additionally, equitable adjustments will be made to the outstanding warrants in accordance with the reverse stock split ratio. The reverse stock split will convert every one hundred shares of the pre-split common stock into one post-split share, with all fractional shares rounded up. The new CUSIP number...Show More
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has filed an amendment to its Form 8-K with the U.S. Securities and Exchange Commission. The amendment, dated May 15, 2024, clarifies details regarding the company's previously announced reverse stock split. The amendment specifies that only the company's common stock, not its public warrants, will begin trading on a split-adjusted basis at the market open on May 17, 2024. Additionally, equitable adjustments will be made to the outstanding warrants in accordance with the reverse stock split ratio. The reverse stock split will convert every one hundred shares of the pre-split common stock into one post-split share, with all fractional shares rounded up. The new CUSIP number for the common stock will be 42254E302 post-split. The exercise price for the public warrants will be adjusted to $425.00 per share, reflecting the reverse split ratio. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively, although the CUSIP for the public warrants will not change.
在纳斯达克股票市场上市的公司Heart Test Laboratories, Inc. 已向美国证券交易委员会提交了其8-K表的修正案。该修正案于2024年5月15日发布,澄清了有关该公司先前宣布的反向股票拆分的细节。该修正案规定,只有公司的普通股,而不是其公开认股权证,将在2024年5月17日开盘时开始按拆分调整后的基础上交易。此外,将根据反向股票分割比率对未偿还的认股权证进行公平调整。反向股票拆分将把拆分前普通股的每一百股转换为拆分后的一股,所有零星股票四舍五入。拆分后,普通股的新CUSIP号码将为 42254E302。公开认股权证的行使价将调整为每股425.00美元,反映反向拆分比率。尽管公开认股权证的CUSIP不会改变,但普通股和公开认股权证的交易代码将分别保持为 “HSCS” 和 “HSCSW”。
在纳斯达克股票市场上市的公司Heart Test Laboratories, Inc. 已向美国证券交易委员会提交了其8-K表的修正案。该修正案于2024年5月15日发布,澄清了有关该公司先前宣布的反向股票拆分的细节。该修正案规定,只有公司的普通股,而不是其公开认股权证,将在2024年5月17日开盘时开始按拆分调整后的基础上交易。此外,将根据反向股票分割比率对未偿还的认股权证进行公平调整。反向股票拆分将把拆分前普通股的每一百股转换为拆分后的一股,所有零星股票四舍五入。拆分后,普通股的新CUSIP号码将为 42254E302。公开认股权证的行使价将调整为每股425.00美元,反映反向拆分比率。尽管公开认股权证的CUSIP不会改变,但普通股和公开认股权证的交易代码将分别保持为 “HSCS” 和 “HSCSW”。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息